SCHEMBL4776276

SCHEMBL4776276

CCCCNc1cc[c]cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 2/20 0.46
TLR8 Q9NR97 4/20 0.46
HRH4 Q9H3N8 4/20 0.41
CNR2 P34972 1/20 0.40
DNM2 P50570 2/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
BCHE P06276 1/20 0.37
TRPC3 Q13507 1/20 0.37
TRPC4 Q9UBN4 1/20 0.37
TRPC5 Q9UL62 1/20 0.37
CDC7 O00311 1/20 0.36
ROCK2 O75116 1/20 0.36
MAP4K4 O95819 1/20 0.36
PIM1 P11309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL991740 0.89 HCAR3 (0.44) HCAR3TLR8DNM2ALDH1A1LMNA
SCHEMBL27453738 0.82 HRH3 (0.47) HRH4ALDH1A1IRAK4
SCHEMBL995044 0.81 CYP2C19 (0.45) DNM2MAPK1IRAK4
SCHEMBL2067353 0.81
SCHEMBL5896994 0.81 HRH3 (0.42) HRH4ALDH1A1PIM1
SCHEMBL4769966 0.78 USP2 (0.37) HCAR3ALDH1A1TP53MAPK1SMN1; SMN2
SCHEMBL4777990 0.78 CHEK1 (0.37) HRH4SMN1; SMN2CDC7ROCK2MAP4K4
SCHEMBL182723 0.78 KDM4E (0.42) ALDH1A1LMNAMAPK1ROCK2MAP4K4
SCHEMBL933094 0.77 CYP2C19 (0.56) HRH4DNM2MAP4K4
SCHEMBL182952 0.77 HCAR3 (0.48) HCAR3ALDH1A1TSHRCDC7ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO claimed
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A HCAR3 2670/4885TLR8 3948/4885HRH4 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.